Search Results for "Psychosis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Psychosis. Results 51 to 60 of 72 total matches.

Aptensio XR - Another Long-Acting Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
be used with caution in patients with a history of mania, psychosis, drug dependence, or alcoholism ...
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):101-3 |  Show IntroductionHide Introduction

Nabilone (Cesamet) for Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006  (Issue 1249)
, dysphoria, depression, visual hallucinations and psychosis can occur, especially in older patients ...
Nabilone, an oral synthetic cannabinoid similar to delta-9-tetrahydrocannabinol (THC), the active ingredient in marijuana, has recently been reintroduced to the US market (Cesamet - Valeant) after a 17-year absence. The previous manufacturer discontinued marketing of the drug for commercial reasons. Nabilone is classified as a Schedule II controlled substance.
Med Lett Drugs Ther. 2006 Dec 4;48(1249):103-4 |  Show IntroductionHide Introduction

Paliperidone (Invega) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007  (Issue 1256)
is not approved for use in demented elderly patients with psychosis, in whom increased mortality ...
Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone (Risperdal - Janssen), which is scheduled to lose its patent exclusivity in December 2007.
Med Lett Drugs Ther. 2007 Mar 12;49(1256):21-3 |  Show IntroductionHide Introduction

Jornay PM - Evening-Dosed Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • Aug 12, 2019  (Issue 1578)
; these drugs should be used with caution in patients with a history of mania, psychosis, drug dependence ...
The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients >6 years old. Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning.
Med Lett Drugs Ther. 2019 Aug 12;61(1578):126-8 |  Show IntroductionHide Introduction

Dextromethorphan/Bupropion (Auvelity) for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
, dose-related seizures, and neuropsychiatric reactions, including psychosis.2 Auvelity ...
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion (Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):201-3 |  Show IntroductionHide Introduction

Lumateperone (Caplyta) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020  (Issue 1603)
an increased risk of death in elderly patients with dementia-related psychosis. DRUG INTERACTIONS ...
The FDA has approved lumateperone (Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):113-6 |  Show IntroductionHide Introduction

Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
ranging from heightened anxiety to psychosis, seizures, and suicide can occur with rapid dosage ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10   doi:10.58347/tml.2023.1667b |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
/sedation, dizziness, fatigue, nausea/vomiting, anxiety, depression Rare: aggression, psychosis ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Acute Reactions to Drugs of Abuse

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2002  (Issue 1125)
, may cause psychosis or violent behavior; restraints and a benzodiazepine may be needed. A common method ...
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.
Med Lett Drugs Ther. 2002 Mar 4;44(1125):21-4 |  Show IntroductionHide Introduction

Drugs for Parasitic Infections

   
Treatment Guidelines from The Medical Letter • Aug 01, 2013  (Issue 143)
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most parasitic infections.
Treat Guidel Med Lett. 2013 Aug;11(143):e1-15 |  Show IntroductionHide Introduction